Quo-Test enables clinicians to make a rapid determination of diabetes management , thereby improving patients’ experience, thanks to the fast and accurate results obtained from the machine in just four minutes from 4μl of blood from finger prick or venous sample. The user-friendly device has a multi-lingual menu and allows for efficient data handling, with a barcode reader and storage of up to 7,000 results, which can be downloaded to a computer via a USB port.
Quo-Test uses a patented Boronate Fluorescence Quenching Technology (BFQT): a simple, fast and accurate method, based on the well-documented boronate affinity for glycated haemoglobin, which is not affected by haemoglobin variants. Although Quo-Test has been developed to be used in a point of care setting, it is a professional product providing laboratory level accuracy, reporting its results in IFCC and DCCT standards (Mono S & JDS reporting are also available). The CE marked analyser has been approved by China's SFDA for the monitoring of HbA1c in diabetes patients and is manufactured in the UK by EKF Diagnostics Group company Quotient Diagnostics Ltd (ISO13485:2003 certified).
To find out more about EKF Quo-Test please visit www.ekfdiagnostics.com
About EKF Diagnostics Holdings plc
The EKF Diagnostics Group has expertise across the entire in vitro diagnostics chain, from fermentation and enzyme production, to the manufacture of liquid reagents, the design and building of world-class diagnostic devices and the distribution of rapid test kits for infectious diseases and pregnancy. The EKF range of analysers are a trusted brand in GP surgeries, pharmacies, blood banks, sports clinics, hospitals and laboratories for the measurement of glucose, lactate, haemoglobin, haematocrit and HbA1c.
To date, the EKF Diagnostics Group has distributors in more than 70 locations around the globe. EKF Diagnostics’